Taletrectinib Adipate Patent Expiration

Taletrectinib Adipate was first introduced by Nuvation Bio Inc in its drug Ibtrozi on Jun 11, 2025.


Taletrectinib Adipate Patents

Given below is the list of patents protecting Taletrectinib Adipate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ibtrozi US9187489 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors Jun 03, 2033 Nuvation
Ibtrozi US9751887 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors Jun 03, 2033 Nuvation



Taletrectinib Adipate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List